April 5 (Reuters) – Pfizer Inc’s drug for multiple inflammatory diseases was approved in the United States, making it the second biosimilar to be approved by the U.S. Food and Drug Administration.
The post FDA approves Pfizer’s biosimilar for inflammatory diseases appeared first on NASDAQ.